Mohammad Mehdi Amiri

Mohammad Mehdi Amiri


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2018 in Reviews in Medical Virology
Verified
Journal Article
Closed access
PDF file
FSForough Golsaz Shirazi
Forough Golsaz Shirazi
MAMohammad Mehdi Amiri
Mohammad Mehdi Amiri
FSFazel Shokri
Fazel Shokri

13 August 2019 in Neurotoxicity Research
Verified
Journal Article
Closed access
SGSomayeh Ghotloo
Somayeh Ghotloo
FGForough Golsaz-Shirazi
Forough Golsaz-Shirazi
MAMohammad Mehdi Amiri
Mohammad Mehdi Amiri
MJMahmood Jeddi-Tehrani
Mahmood Jeddi-Tehrani
FSFazel Shokri
Fazel Shokri

1 October 2009 in Indian Journal of Medical Microbiology
Verified
Journal Article
Open access
PDF file
MRMahdi Rohani
Mahdi Rohani
PFParissa Farnia
Parissa Farnia
MNM Naderi Nasab
M Naderi Nasab
RMR Moniri
R Moniri
MTM Torfeh
M Torfeh
MAMohammad Mehdi Amiri
Mohammad Mehdi Amiri
Purpose : The purpose of this study was to understand the molecular epidemiology of tuberculosis in Khorasan province of Iran was studied by spoligotyping 113 Mycobacterium tuberculosis isolates. The spoligotyping results were in comparison to the word Spoligotyping Database of Institute Pasteur de Guadeloupe (SpolDB4). Spoligotyping data from Iran has rarely been described and there is limited information on the major circulating clades of M. tuberculosis in Iran. Materials and Methods: Spoligotyping was performed on 113 M. tuberculosis isolates from Mashhad patients between November 2004 and September 2005. Results: The study found 57 spoligopatterns. 17 clusters and 32 true orphan genotype. The biggest cluster with 13 isolates had not been previously reported. The Beijing genotype was seen in eight (7.1%) isolates. Conclusions: Genotyping and Spoligotyping gives a unifying framework for both epidemiology and evolutionary analysis of M. tuberculosis populations.

9 June 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
MRMahdi Rohani
Mahdi Rohani
FSFattah Sotoodehnejadnematalahi
Fattah Sotoodehnejadnematalahi
MAMohammad Mehdi Amiri
Mohammad Mehdi Amiri
MPMohammad Reza Pourshafie
Mohammad Reza Pourshafie
MRMahdi Rohani
Mahdi Rohani
Probiotic supplements consumed adequately at the proper time can affect health by modulating inflammatory pathways in gastrointestinal epithelial cells and modifying the resultant inflammatory response. The current study applied in vitro models to investigate the effectiveness of probiotics in modulating inflammatory pathways and altering inflammatory gene expression in gastrointestinal epithelial cells, with the ultimate goal of promoting probiotic consumption as a therapeutic and preventive measure for chronic inflammatory bowel conditions. HT-29 cells were treated with Gram-negative bacteria to evaluate the changes in pathways related to inflammation activities before and after treatment with a Lactobacillus spp. cocktail (L. plantarum, L. rhamnosus, L. brevis, and L. ruteri) and a Bifidobacterium spp. cocktail (B. bifidum, B. langum, and B. breve) using the real-time PCR method and ELISA for IL-1β and IL-6 as pro-inflammatory cytokines. The results showed that the expression of NF-κB signaling pathway genes and IL-1β and IL-6 cytokines increased after exposure to Gram-negative components. In contrast, all probiotic combinations significantly decreased the expression of genes and the secretion of cytokines. However, this decrease was significantly smaller in cells that underwent probiotic treatment after inflammation induction. In addition, cocktails containing combined Lactobacillus and Bifidobacterium demonstrated robust anti-inflammatory activity relative to solo cocktails. Our observations confirm that probiotic consumption could positively impact inflammatory conditions and alleviate inflammatory symptoms; they can be particularly effective as a preventive measure. Our study provides preliminary evidence to support the lifetime consumption of probiotics.

17 February 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MMMehdi Mohammadi
Mehdi Mohammadi
MJMahmood Jeddi-Tehrani
Mahmood Jeddi-Tehrani
FGForough Golsaz-Shirazi
Forough Golsaz-Shirazi
MAMohammad Arjmand
Mohammad Arjmand
TBTannaz Bahadori
Tannaz Bahadori
FSFazel Shokri
Fazel Shokri
Overexpression of HER2 has been reported in many types of cancer, making it a perfect candidate for targeted immunotherapy. The combination of two FDA approved monoclonal antibodies (mAbs), trastuzumab and pertuzumab, has more robust anti-tumor activity in patients with HER2-overexpressing breast cancer. We recently produced a new humanized anti-HER2 mAb, hersintuzumab, which recognizes a different epitope than trastuzumab and pertuzumab on HER2. This mAb, in combination with trastuzumab, exhibits more potent anti-tumor activity than each parental mAb alone. Here we have developed a novel bispecific anti-HER2 antibody (BsAb) designated as trasintuzumab, composed of trastuzumab and hersintuzumab, using dual variable domain immunoglobulin (DVD-Ig) technology. Both variable domains of trasintuzumab are fully functional and have similar affinities to the parental mAbs and are also able to bind to natural HER2 on the surface of several HER2-expressing cell lines. Trasintuzumab was found to inhibit the growth of different types of tumor cell lines through suppression of the AKT and ERK signaling pathways as efficiently as the combination of the parental mAbs. It also induced tumor regression as potently as the combination of the two mAbs in nude mice bearing ovarian and gastric cancer xenografts. Our data suggest that trasintuzumab may be a promising BsAb therapeutic candidate for the treatment of HER2-overexpressing cancers.

10 December 2013 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
FSForough Golsaz Shirazi
Forough Golsaz Shirazi
HMHamed Mohammadi
Hamed Mohammadi
MAMohammad Mehdi Amiri
Mohammad Mehdi Amiri
KSKatrin Singethan
Katrin Singethan
YXYuchen Xia
Yuchen Xia
FSFazel Shokri
Fazel Shokri